background
influenza
repres
seriou
public
health
concern
emerg
resist
antiinfluenza
drug
underlin
need
develop
new
drug
studi
aim
evalu
antiinfluenza
viral
activ
possibl
mechan
phenanthren
medicin
plant
bletilla
striata
orchidacea
famili
method
twelv
phenanthren
isol
identifi
b
striata
influenza
viru
propag
embryon
chicken
egg
use
phenanthren
mix
viru
incub
h
inocul
embryon
chicken
egg
via
allanto
rout
survey
antivir
activ
vivo
mt
base
assay
perform
evalu
reduct
cytopath
effect
induc
madindarbi
canin
kidney
mdck
cell
hemagglutin
inhibit
assay
use
studi
blockag
viru
receptor
phenanthren
neuraminidas
na
inhibit
assay
evalu
effect
releas
viru
synthesi
influenza
viral
matrix
protein
mrna
respons
compound
treatment
measur
realtim
polymeras
chain
reaction
result
studi
show
phenanthren
significantli
inhibit
virus
vivo
inhibit
rate
respect
mdck
model
phenanthren
show
signific
antivir
activ
administ
pretreat
phenanthren
exhibit
inhibitori
activ
simultan
treatment
inhibit
concentr
ic
rang
ic
rang
posttreat
assay
compound
exhibit
inhibitori
effect
na
compound
result
reduc
transcript
viru
matrix
protein
mrna
howev
compound
could
inhibit
hemagglutin
influenza
viru
conclus
phenanthren
b
striata
strong
antiinfluenza
viral
activ
embryon
egg
mdck
model
diphenanthren
seem
stronger
inhibit
activ
compar
monophenanthren
influenza
virus
respons
season
epidem
occasion
pandem
caus
signific
morbid
mortal
vaccin
need
reformul
almost
everi
year
owe
antigen
drift
time
product
pandem
vaccin
remain
problemat
limit
current
technolog
antivir
drug
play
signific
role
control
spread
diseas
emerg
drugresist
viral
strain
report
occasion
becom
seriou
public
health
concern
global
therefor
safe
effect
new
antivir
drug
need
develop
urgent
combat
viral
infect
either
therapeut
prophylact
purpos
two
surfac
glycoprotein
present
envelop
influenza
viru
hemagglutinin
ha
neuraminidas
na
life
cycl
influenza
viru
begin
viral
ha
bind
sialic
acid
sa
receptor
host
cell
surfac
follow
intern
viru
receptormedi
endocytosi
subsequ
endosom
acidif
alter
conform
ha
lead
fusion
host
viral
membran
allow
releas
viral
nucleoprotein
np
cytoplasm
nucleu
infect
cell
viral
rna
transcrib
mrna
replic
final
newli
synthes
viral
ribonucleoprotein
vrnp
export
cytoplasm
packag
matur
virion
releas
cell
surfac
depend
cleav
sa
receptor
sialidas
therefor
ha
play
key
role
initi
viral
infect
bind
sacontain
receptor
host
cell
thu
mediat
subsequ
viral
entri
membran
fusion
na
cleav
specif
linkag
sa
receptor
result
releas
newli
form
virion
infect
cell
oseltamivir
market
trade
name
tamiflu
first
oral
administ
commerci
develop
na
inhibitor
discov
use
shikim
acid
start
point
synthesi
shikim
acid
origin
avail
extract
chines
star
anis
oseltamivir
world
health
organ
list
essenti
medicin
list
import
medic
need
basic
health
system
howev
found
substanti
number
patient
might
becom
oseltamivirresist
result
oseltamivir
use
oseltamivir
resist
might
significantli
associ
pneumonia
tuber
bletilla
striata
orchidacea
famili
wellknown
tradit
chines
herb
known
baiji
chines
chines
pharmacopoeia
state
b
striata
support
hemostasi
detumesc
promot
recoveri
phytochem
research
reveal
bletilla
contain
polysaccharid
bibenzyl
phenanthren
dihydrophenanthren
flavonoid
phenol
compound
addit
report
antimicrobi
antioxid
antiinflammatori
activ
chemic
compon
b
striata
dpph
radicalscaveng
ferricreduc
antioxid
tyrosinaseinhibitori
activ
studi
furthermor
six
biphenanthren
separ
antibacteri
activ
report
present
studi
antiinfluenza
viral
activ
phenanthren
investig
antivir
mechan
inhibit
activ
na
ha
explor
rhizom
b
striata
orchidacea
famili
collect
tuankou
town
zhejiang
provinc
peopl
republ
china
authent
prof
zs
ding
one
author
voucher
specimen
deposit
zhejiang
chines
medic
univers
specimen
number
organ
extract
b
striata
prepar
via
macer
ethanol
reflux
four
time
time
min
remov
solvent
reduc
pressur
residu
suspend
l
h
partit
etoac
l
yield
etoacsolubl
fraction
fraction
purifi
silica
gel
column
elut
gradient
solvent
system
purifi
use
highperform
liquid
chromatographi
hplc
system
nm
mlmin
venusil
xbp
column
bonnaagela
usa
mm
elut
gradient
mixtur
acetonitril
water
formic
acid
structur
determin
use
extens
spectroscop
analysi
includ
uv
lcm
influenza
viru
strain
use
studi
obtain
zhejiang
provinci
center
diseas
control
prevent
propag
allanto
caviti
chicken
egg
harvest
h
inocul
pool
allanto
fluid
brief
centrifug
rpm
min
hemagglutin
titer
measur
hemagglutin
test
virul
viru
determin
egg
infect
dose
eid
analysi
chicken
egg
tissu
cultur
infect
dose
tcid
analysi
madindarbi
canin
kidney
mdck
epitheli
cell
seri
tenfold
dilut
viru
inocul
chick
allanto
caviti
mlembryo
dilut
embryo
h
harvest
hemagglutin
test
perform
posit
rate
dilut
record
eid
evalu
use
method
reed
muench
approxim
cellswel
seed
micropl
minimum
essenti
medium
mem
fetal
bovin
serum
fb
humidifi
co
incub
monolay
confluent
cell
wash
twice
phosphatebuff
salin
pb
infect
seri
tenfold
viru
dilut
noviru
use
control
dilut
replic
mainten
medium
mem
contain
uml
penicillin
g
streptomycin
supplement
ethyl
chloromethyl
ketonetr
trypsin
sigmaaldrich
compani
ltd
uk
incub
co
develop
cytopath
effect
cpe
host
cell
observ
daili
cpe
observ
noviru
control
cell
remain
normal
cpe
record
five
grade
round
cell
increas
refractil
loss
adherencedetach
morpholog
chang
cell
fig
tcid
evalu
use
method
reed
muench
variou
concentr
compound
prepar
dilut
pb
mix
equal
volum
influenza
viru
eid
compoundviru
mixtur
incub
h
swab
egg
punch
inocul
compoundviru
mixtur
via
allanto
rout
pb
viru
without
treatment
use
control
posit
control
oseltamivir
phosphat
triplic
test
perform
compound
viru
egg
incub
h
allanto
fluid
harvest
viru
titer
measur
use
hemagglutin
test
logarithm
transform
log
calcul
done
ha
titer
influenza
viru
inhibitori
activ
calcul
inhibit
x
x
x
log
ha
titer
viral
control
log
ha
titer
test
sampl
mtsbase
assay
perform
evalu
cytotox
effect
test
compound
mdck
cell
approxim
cellswel
seed
micropl
mem
fb
humidifi
co
incub
monolay
confluent
cell
wash
twice
pb
treat
compound
dilut
serum
free
mem
incub
h
mt
ad
well
cell
incub
h
absorb
nm
determin
use
micropl
reader
cell
viabil
calcul
use
follow
formula
cell
viabil
drug
treatmentbackground
controlbackground
halfmaxim
cytotox
concentr
cc
compound
defin
concentr
reduc
compoundtr
cell
untreat
cell
three
test
develop
noncytotox
concentr
compound
determin
use
cytotox
test
pretreat
noncytotox
concentr
compound
ad
cell
incub
h
remov
cell
wash
infect
influenza
tcid
h
viru
remov
medium
replac
serumfre
mem
mainten
medium
simultan
treatment
noncytotox
concentr
compound
viru
tcid
ad
cell
monolay
simultan
h
supplement
mainten
medium
posttreat
mdck
cell
infect
viru
h
test
compound
ad
h
supplement
mainten
medium
cell
without
treatment
use
notinfect
control
pb
instead
compound
use
infect
control
oseltamivir
phosphat
posit
control
test
perform
triplic
cultur
incub
h
co
atmospher
infect
control
show
complet
cpe
almost
cell
affect
cell
sheet
came
wall
cultur
well
observ
light
microscop
mt
ad
well
cell
incub
h
absorb
nm
determin
use
micropl
reader
cpe
inhib
inhibit
concentr
calcul
use
reedmuench
analysi
hemagglutin
inhibit
assay
use
studi
whether
compound
could
block
sacontain
receptor
phenanthren
b
striata
oseltamivir
phosphat
test
fresh
guinea
pig
blood
collect
laboratori
anim
research
center
zhejiang
chines
medic
univers
supplement
sodium
citrat
steril
water
red
blood
cell
rbc
separ
centrifug
min
room
temperatur
wash
three
time
steril
pb
suspend
concentr
least
number
viru
particl
abl
agglutin
guinea
pig
rbc
determin
serial
viru
dilut
four
hemagglutin
unit
hau
pb
instead
compound
use
hemagglutin
posit
control
noviru
rbc
hemagglutin
neg
control
compound
serial
twofold
dilut
pb
mix
hau
influenza
viru
suspens
incub
h
mix
equal
volum
guinea
pig
rbc
suspens
h
room
temperatur
monitor
agglutin
neuraminidas
inhibit
assay
use
evalu
effect
compound
neuraminidas
activ
influenza
viru
accord
instruct
neuraminidas
inhibitor
screen
kit
beyotim
china
c
fluoresc
control
enzym
buffer
substrat
min
incub
c
fluoresc
control
buffer
substrat
fluoresc
test
sampl
enzym
sampl
solut
substrat
incub
standard
curv
made
plot
percentag
fluoresc
inhibit
rel
activ
viru
control
log
concentr
addit
oseltamivir
phosphat
use
posit
control
na
reaction
buffer
mix
equal
volum
twofold
dilut
compound
incub
equal
volum
substrat
solut
acid
sodium
ad
mixtur
incub
min
fluoresc
intens
measur
use
fluoresc
plate
reader
excit
wavelength
nm
emiss
wavelength
nm
inhibitori
concentr
ic
calcul
regress
analysi
r
repres
mean
valu
three
independ
experi
evalu
express
level
matrix
protein
mrna
influenza
viru
use
quantit
realtim
polymeras
chain
reaction
rtpcr
express
level
matrix
protein
mrna
influenza
viru
determin
revers
transcript
quantit
rtpcr
evalu
effect
compound
viru
replic
mdck
cell
grown
approxim
confluenc
plate
cell
per
well
data
analyz
use
mode
normal
express
data
present
mean
standard
deviat
sd
comparison
pair
perform
student
test
use
spss
version
spss
il
usa
p
valu
consid
signific
ic
cc
valu
calcul
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
usa
isol
phenanthren
medicin
plant
bletilla
striata
structur
name
phenanthren
list
tabl
chromatogram
fig
spectra
addit
file
well
spectral
data
compound
addit
file
also
provid
compound
report
compound
new
discoveri
studi
influenza
viru
propag
chicken
egg
dose
evalu
eid
ml
suitabl
dilut
compound
set
accord
solubl
toxic
swab
egg
inocul
eid
viru
mixtur
via
allanto
rout
h
viru
titer
allanto
fluid
measur
hemagglutin
test
result
show
b
striata
compound
signific
antivir
activ
influenza
viru
embryon
hen
egg
tabl
chemic
structur
phenanthren
tuber
bletilla
striata
continu
tabl
compound
best
although
seem
less
effici
oseltamivir
show
inhibit
rate
mmol
egg
result
concentr
present
tabl
first
set
experi
cytotox
compound
measur
use
mtsbase
assay
found
compound
reduc
viabil
tabl
morpholog
altern
loss
cell
viabil
modif
cell
multipl
rate
could
observ
cell
treat
b
striata
compound
select
work
dose
compound
mtsbase
cpe
reduct
assay
mdck
model
use
confirm
antivir
activ
antivir
effect
compound
quantifi
use
select
index
si
ratio
cc
versu
ic
valu
tabl
data
cpe
reduct
assay
demonstr
b
striata
compound
exhibit
inhibitori
antivir
effect
two
group
simultan
treatment
posttreat
simultan
treatment
assay
compound
exhibit
inhibitori
activ
influenza
viru
ic
valu
rang
compound
show
maximum
inhibitori
activ
fig
ic
valu
b
striata
compound
rang
posttreat
assay
fig
compound
show
potent
activ
si
though
lower
valu
oseltamivir
simultan
treatment
assay
result
indic
treatment
b
striata
compound
viru
entri
abrog
viru
infect
henc
hemagglutin
inhibit
assay
use
test
hypothesi
b
striata
compound
interfer
viral
attach
howev
result
show
compound
could
inhibit
hemagglutin
influenza
viru
neither
oseltamivir
fig
na
activ
assay
na
standard
curv
detail
data
shown
addit
file
fig
tabl
perform
detect
antivir
effect
b
striata
compound
determin
mechan
result
tabl
show
compound
exhibit
inhibitori
effect
na
dosedepend
manner
ic
valu
rang
compound
display
higher
inhibitori
activ
na
known
na
inhibitor
oseltamivir
show
much
lower
ic
synthesi
influenza
viral
matrix
protein
mrna
compar
untreat
infect
cell
infect
cell
treat
compound
identifi
inhibitori
effect
compound
influenza
viru
replic
rna
extract
perform
h
influenza
viru
infect
level
intracellular
influenza
rna
measur
quantit
rtpcr
show
reduct
matrix
protein
mrna
transcript
cell
treat
b
striata
compound
compar
untreat
infect
cell
fig
compound
show
stronger
inhibitori
effect
compound
effici
even
power
oseltamivir
result
indic
blockag
viru
replic
one
mechan
b
striata
compound
exert
antivir
effect
influenza
remain
seriou
problem
mani
countri
long
histori
outbreak
epidem
recent
pandem
develop
viral
biolog
novel
antivir
strategi
target
virus
ha
ion
channel
protein
rnadepend
rna
polymeras
rdrp
np
ns
na
develop
two
main
class
antivir
drug
clinic
use
influenza
inhibitor
viral
protein
amantadin
symmetrel
rimantadin
flumadin
neuraminidas
inhibitor
zanamivir
relenza
oseltamivir
tamiflu
protein
inhibitor
amantadin
consist
adamantan
backbon
amino
group
substitut
result
show
antivir
effect
less
inhibit
one
four
methyn
posit
rimantadin
close
relat
deriv
adamantan
similar
biolog
properti
fig
accord
us
center
diseas
control
prevent
season
pandem
flu
sampl
test
shown
resist
adamantan
amantadin
longer
recommend
treatment
influenza
unit
state
new
protein
inhibitor
urgent
need
channel
transport
proton
vacuolar
space
interior
virion
acidif
interior
result
dissoci
ribonucleoprotein
onset
viral
replic
amantadin
rimantadin
function
mechanist
ident
fashion
enter
barrel
tetramer
channel
block
pore
function
ie
proton
transloc
resist
drug
class
consequ
mutat
porelin
residu
channel
lead
hemagglutin
inhibit
phenanthren
bletilla
striata
hemagglutin
inhibit
assay
use
test
hypothesi
b
striata
compound
interfer
viral
attach
howev
result
show
compound
could
inhibit
hemagglutin
influenza
viru
inabl
steric
bulki
adamantan
ring
share
enter
usual
way
channel
neuraminidas
inhibitor
serv
competit
inhibitor
activ
viral
neuraminidas
na
enzym
sa
found
glycoprotein
surfac
normal
host
cell
block
activ
enzym
oseltamivir
prevent
new
viral
particl
releas
cleav
termin
sa
glycosyl
hemagglutinin
fig
wikipedia
discoveri
first
design
influenza
viru
neuraminidas
inhibitor
antiinfluenza
drug
zanamivir
subsequ
oseltamivir
inspir
number
continu
effort
toward
discoveri
nextgener
antiinfluenza
drug
phenanthren
polycycl
aromat
hydrocarbon
compos
three
fuse
benzen
ring
name
phenanthren
composit
phenyl
anthracen
natur
phenanthren
origin
biosynthet
stilbenoid
via
oxid
coupl
aromat
ring
demonstr
varieti
pharmacolog
effect
antiallerg
antiinflammatori
antimicrobi
cytotox
spasmolyt
activ
cc
coupl
two
phenanthren
linkag
produc
rare
occur
biphenanthren
show
interest
atropisomer
featur
due
hinder
rotat
linkag
bond
oh
ome
group
present
nearbi
synthet
chiral
biphenanthren
appli
effect
enantioselect
catalyst
ligand
atropisomer
featur
mani
natur
biphenanthren
alway
discuss
fulli
scientif
public
optic
activ
natur
occur
biphenanthren
blestriaren
c
shown
undergo
rapid
racem
even
daylight
compound
use
fight
viral
infect
base
phenanthren
core
includ
compound
plant
virus
human
virus
secret
phenanthren
natur
defens
mechan
plant
fungal
infect
phenanthren
b
striata
efficaci
gramposit
bacteria
weak
efficac
fungi
phenanthren
taxol
communi
efficaci
vesicular
stomat
viru
human
rhinoviru
serotyp
phenanthren
deriv
show
efficaci
coronavirus
antivir
properti
phenanthren
b
striata
influenza
viru
investig
studi
use
embryon
hen
egg
confirm
compound
exert
signific
inhibitori
effect
mdck
model
compound
exhibit
cpe
reduct
activ
studi
show
phenanthren
b
striata
strong
antiinfluenza
viral
activ
furthermor
ha
matrix
protein
na
employ
target
studi
possibl
mechan
b
striata
compound
serv
matrix
protein
inhibitor
result
reduct
mrna
transcript
functionstructur
relationship
compound
whether
interfer
proton
channel
need
explor
compound
exhibit
inhibitori
effect
na
compound
display
higher
inhibitori
activ
na
exoglycosidas
destroy
ha
receptor
cleav
ketosid
linkag
exist
termin
sa
sugar
residu
nacetylneuramin
acid
contain
receptor
surfac
host
cell
neuraminidas
inhibitor
commonli
interfer
enzym
activ
mimick
natur
substrat
fit
activ
site
neuraminidas
enzym
bind
effici
compound
neuraminidas
major
determin
inhibitori
activ
structureact
relationship
new
neuraminidas
inhibitor
prove
better
molecular
properti
higher
effici
neuraminidas
receptor
compar
zanamivir
oseltamivir
present
studi
compound
show
efficaci
egg
model
reason
similar
efficaci
present
unknown
inde
four
compound
share
molecular
structur
result
could
bias
small
number
egg
use
experi
also
possibl
compound
share
mechan
studi
addit
compound
inhibit
influenza
viru
two
mechan
reason
dual
inhibit
current
unknown
addit
studi
necessari
better
character
compound
studi
indic
diphenanthren
compound
stronger
inhibitori
activ
compar
monophenanthren
compound
mdck
model
antivir
effect
monophenanthren
less
except
compound
effect
diphenanthren
higher
ic
could
calcul
might
hydroxyl
group
impact
hydrophilicityhydrophob
compound
diphenanthren
share
hydroxyl
group
howev
hydroxyl
group
affect
antivir
activ
still
need
investig
compound
serv
matrix
protein
inhibitor
result
reduct
mrna
transcript
compound
exhibit
inhibitori
effect
na
addit
studi
requir
elucid
exact
mechan
compound
